PSC Australia
  • Home
  • PSC
  • Resources
  • PSC Research
  • Rare Diseases
  • Contact Us

Scientific Research
This page is in a'blog' format with the latest scientific PSC research identified by Google Scholar, Readbyqmx.com and other sources added regularly.

Systemic therapy for cholangiocarcinoma

6/22/2014

0 Comments

 
Systemic therapy for cholangiocarcinoma

Saeed Sadeghi and Richard S. Finn. Clinical Liver Disease, 2014, Special Issue: Autoimmune Liver Disease, Part 4, Volume 3, Issue 4, pages 86–89

Abstract

Cholangiocarcinoma (CCA) is an increasingly common biliary malignancy and accounting for 3% of all gastrointestinal tumors. In the United States, the incidence is 1 to 2 cases per 100,000 population and is uncommon compared with other cancer types. While the incidence of intrahepatic CCAs has been rising in industrialized countries, the incidence of extrahepatic CCA is declining worldwide.1 CCA continues to have a high mortality, with a 5-year survival rate of 10%.[2] In the Western world, the most commonly associated risk factor for CCA is primary sclerosing cholangitis, with an annual risk of 0.5%-1.5%  . . . Please click here to read the full text of this article

0 Comments

Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon

6/22/2014

0 Comments

 
Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon

Roger W. Chapman. Clinical Liver Disease Special Issue: Autoimmune Liver Disease, Part 4, 2014, Volume 3, Issue 4,  pages 83–85,

Abstract

As discussed in companion articles in CLD, the clinical course of large duct primary sclerosing cholangitis (PSC) is highly variable and unpredictable.[1, 2] Although the median survival from presentation to death or liver transplantation in symptomatic patients is approximately 10-12 years, 75% of asymptomatic patients will survive 15 years or more. A recent Dutch study has shown an overall median survival of 22 years in PSC patients.[3] . . . Please click here for the full article

An interview with the author and a video presentation of this article is available by clicking here.

0 Comments

Endoscopic management of primary sclerosing cholangitis

6/22/2014

0 Comments

 
Endoscopic management of primary sclerosing cholangiti

Ryan Law D.O. and Todd H. Baron M.D., Clinical Liver Disease: Special Issue: Autoimmune Liver Disease, Part 4, Volume 3, Issue 4, pages 79–82, April 2014

Abstract

Primary sclerosing cholangitis (PSC) is a progressive, chronic fibroinflammatory disorder involving the intra- and extrahepatic biliary tree that can lead to cirrhosis and liver failure in a subset of patients. Additionally, progression of PSC can lead to life-threatening episodes of ascending cholangitis and the development of cholangiocarcinoma (CCA). Herein we describe the endoscopic evaluation and therapeutic management of PSC and CCA . . . Please click here to read the full article

0 Comments

Update on inflammatory bowel disease in patients with primary sclerosing cholangitis

6/22/2014

0 Comments

 
Update on inflammatory bowel disease in patients with primary sclerosing cholangitis

Christos Tsaitas, Anysia Semertzidou and Emmanouil Sinakos. World J Hepatol. 2014 April 27; 6(4): 1780-187. Published online 2014 April 27. doi: 10.4254/wjh.v6.i4.178.

Abstract

Patients with primary sclerosing cholangitis (PSC) complicated by inflammatory bowel disease (IBD) represent a distinct subset of patients with unique characteristics, which have serious clinical implications. The aim of this literature review was to shed light to the obscure clinical and molecular aspects of the two diseases combined utilizing current data available and putting issues of diagnosis and treatment into perspective. The prevalence of IBD, mainly ulcerative colitis in PSC patients is estimated to be 21%-80%, dependent on screening programs and nationality . . .  Please click here to read further

0 Comments

HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation

6/22/2014

0 Comments

 
HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation

Bjarte Fosby, Sigrid Næss, Johannes R Hov, James Traherne, Kirsten M Boberg, John Trowsdale, Aksel Foss, Pål-Dag Line, Andre Franke, Espen Melum, Helge Scott and Tom H Karlsen. World J Gastroenterol. 2014 April 14; 20(14): 3986-4000. Published online 2014 April 14. doi: 10.3748/wjg.v20.i14.3986.

Abstract

Aim: To investigate influence of human leukocyte antigen (HLA) and killer immunoglobuline-like receptor (KIR) genotypes on risks of acute rejection (AR) after liver transplantation (LTX).

Methods: In this retrospective study we included 143 adult donor-recipient pairs with a minimum of 6 mo follow-up after LTX for whom DNA was available from both donor and recipients. Clinical data, all early complications including episodes and severity of AR and graft/patient survival were registered. The diagnosis of AR was based on clinical, biochemical and histological criteria. All suspected episodes of AR were biopsy confirmed . . .  Please click here to read further
0 Comments

Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis

6/22/2014

0 Comments

 
Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis 

James H. Tabibian, Felicity Enders, Mohamad H. Imam, Gururaj Kolar,  Keith D. Lindor, Jayant A. Talwalkar.
Annals of Hepatology,  2014, May-June, Vol. 13 No. 3, 2014: 384-389

Abstract

Introduction: Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be as- sociated with CCA in a Japanese cohort of PSC patients. Our aim in this study was to determine whether IgE levels predict time to CCA, liver transplantation, or death in a Western (USA-based) cohort of PSC pa- tints. 

Material and methods: Thirty-eight patients with PSC and IgE levels were identified and categorized into low or high IgE groups based on the sample median. Groups were compared with respect to clinical characteristics and adverse endpoint-free survival . . . Please click here to be taken to the full text article

0 Comments

Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Children and Adolescents

6/22/2014

0 Comments

 
Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Children and Adolescents.

Claudia Patricia Rojas, Rajasekhar Bodicharla,  German Campuzano-Zuluaga, Lina Hernandez, and Maria Matilde Rodriguez Posted online on April 22, 2014. (doi:10.3109/15513815.2014.898721

Abstract

Clinical presentation and histopathology of autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) overlap syndrome (OS) are similar, but their management is different. We conducted a pediatric retrospective cross-sectional study of 34 patients with AIH and PSC. AIH had female predominance (74%) and was lower in PSC (45%). 

Read More by clicking here: http://informahealthcare.com/doi/abs/10.3109/15513815.2014.898721
Posted online on April 22, 2014. (doi:10.3109/15513815.2014.898721)

0 Comments

    Research

    Every effort is taken to ensure the research presented is from reputable sources. 

    In order to ensure that copyright is not breached, only a small portion of the abstract is provided here. Clicking on the title will take you to the original journal, or site, where the abstract has been published. Most times only an abstract of an article is available as subscriptions are usually required. Occasionally a full text is made freely available.

    RSS Feed

    News & Updates Blog
    Glossary

    Archives

    December 2016
    September 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014


    Categories

    All
    Adolescence
    Adults
    Antibiotic
    Australia
    Australian
    Autoimmune Diseases
    Autoimmune Hepatitis
    Bezafibrate
    Bile Leak
    Biliary Strictures
    Cancer
    CCA Risk
    Children
    Cholangiocarcinoma
    Cholangitis
    Cholectomy
    Cholestatic Liver Disease
    Colectomy
    Colorectal Cancer
    Consensus Statement
    Crohn's Disease
    Diagnosis
    Drug Therapy
    Endoscopy
    Environmental Factors
    ERCP
    Fibroscan
    Genetics
    Genomes
    Genotypes
    Hepatic Cholestasis
    HLA
    IBD
    IgE Levels
    IgG4
    Inflammatory Bowel Disease
    Itching
    Leaky Gut
    Liver
    Liver Tests
    Liver Transplant
    Living Donor
    Management Of PSC
    MELD Score
    Microbiome
    Organ Donation
    Outcomes
    Paediatric Patients
    Paediatric PSC
    Patient And Graft Survival
    Pets
    Population
    Prognosis
    Pruritus
    PSC
    PSC/AIH
    Quality Of Life
    Questionnaire
    Recurrent PSC
    RPSC
    Sclerosing Cholangitis
    Scoring Systems
    Screening
    Staging
    Staging Systems
    Stem Cells
    Stenosis
    Terminal Restriction Fragment (TRF)
    Treatment
    Ulcerative Colitis
    Ultrasound
    Ultrasound Elastography
    Ursodeoxycholic Acid
    Vancomycin


    RSS Feed


    Page created 09.03.2014
    Updated: 09.04.2014
Disclaimer:  The information presented on this website is intended for information and educational purposes only, and is not intended to be a substitute for medical advice or information in any way. The information is not written by a medical practitioner, and as such it should never be used for diagnostic, treatment or management purposes. If you have questions regarding your medical needs, always seek the advice of your doctor, specialist or other appropriate and qualified health care professional.
This is a non-commercial website, designed and developed to provide relevant information to people living with Primary Sclerosing Cholangitis.
Wallpaper by Gaiam   www.gaiam.com.au

Full Disclaimer
Medical Disclaimer


Privacy & Cookie Policy


Powered by Create your own unique website with customizable templates.

BACK TO TOP

PSC-Australia.com.au
©2014 Health & Education Services | All Rights Reserved

© DivTag Templates Ltd | All Rights Reserved